Quick Answer
Anixa Biosciences Inc reported Cash and Equivalents of $1.24 million for fiscal year 2025.
Anixa Biosciences Inc Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $1.24M | -2.1% |
| 2024 | $1.27M | +38.9% |
| 2023 | $915.0K | -92.6% |
| 2022 | $12.36M | -57.6% |
| 2021 | $29.13M | +353.9% |
| 2020 | $6.42M | +83.8% |
| 2019 | $3.49M | +14.3% |
| 2018 | $3.06M | -8.5% |
| 2017 | $3.34M | +34.2% |
| 2016 | $2.49M | -43.0% |
| 2015 | $4.37M | +30.0% |
| 2014 | $3.36M | +274.2% |
| 2013 | $898.2K | +164.4% |
| 2012 | $339.7K | -56.1% |
| 2011 | $774.0K | -29.3% |
| 2010 | $1.09M | -24.6% |
| 2009 | $1.45M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | $1.55M | +46.9% | +24.4% |
| October 31, 2025 | $1.24M | -2.1% | -16.8% |
| July 31, 2025 | $1.50M | +22.0% | -21.7% |
| April 30, 2025 | $1.91M | +92.0% | +81.4% |
| January 31, 2025 | $1.05M | +5.5% | -17.2% |
| October 31, 2024 | $1.27M | +38.9% | +3.8% |
| July 31, 2024 | $1.23M | -61.7% | +23.1% |
| April 30, 2024 | $995.0K | -82.3% | -0.3% |
- Anixa Biosciences Inc showed a decrease of -2.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2025 period, Anixa Biosciences Inc’s cash and equivalents has declined by 14.3% (from $1.45 million to $1.24 million).
- The most recent figure is from Anixa Biosciences Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on January 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: